EXTRACELLULAR MATRIX MARKET ANALYSIS

Extracellular Matrix Market, By Component Type (Proteins, Glycoproteins, Proteoglycans, Other ECM molecules), By Application (Regenerative Medicine, Tissue Engineering, Wound Healing, Drug Delivery, Cancer Research, Others), By Source (Animal-Derived ECM, Human-Derived ECM, Synthetic ECM), By End-User (Research Institutes and Academic Centers, Biotechnology and Pharmaceutical Companies, Hospitals and Clinics), By Product Type (Hydrogels, Scaffolds, Decellularized ECM, ECM Analogs, Others), By Technology (3D Bioprinting, Nanotechnology, Cell Culture Techniques, Genetic Engineering, Others), By Therapeutic Area (Orthopedics, Dermatology, Cardiology, Neurology, Oncology, Others), By Function (Structural Support, Cellular Communication, Cell Adhesion, Signal Transduction), By Biomaterial Type (Natural ECM, Synthetic ECM), By End-Use Industry (Healthcare, Research and Development, Cosmetics, Pharmaceuticals, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Recent Developments

New product launches

In November 2021, Sanara MedTech Inc., a medical equipment manufacturer, in collaboration with Cook Biotech Inc., a biotechnology company, announced the launch of Fortify Flowable Extracellular Matrix. Fortify Flowable Extracellular Matrix is an advanced wound care device that presents SIS ECM technology in a way that can fill irregular wound shapes and depths.
On March 2, 2023, Convatec Inc., a medical device company, received approval from the U.S. Food and Drug Administration for its InnovaBurn placental extracellular matrix medical device to treat burns and complicated surgical wounds, including second-degree partial-thickness burns.

Acquisition and partnerships

On February 1, 2023, Baxter, a healthcare company, and Miromatrix Medical Inc., a biotechnology company, announced a partnership to develop a therapy for patients with acute liver failure (ALF). The partners will combine Miromatrix Medical Inc. single-use bioengineered liver with Baxter’s PrisMax system, which is designed to provide individualized therapies to patients.
June 2, 2022. Lineage Cell Therapeutics, Inc., a biotechnology company, announced that it had expanded its existing collaboration with Advanced BioMatrix, a biotechnology company. Under the expanded collaboration, Advanced BioMatrix will broaden its current focus of manufacturing and supplying R&D-grade HyStem to the research community to include the development, supply, and/or licensing of clinical/commercial GMP- (Good Manufacturing Practice) grade material for its customers. HyStem is a hydrogel that copies the extracellular matrix that surrounds cells in organs and tissues and is necessary for both tissue structure and cellular activity.